All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Casdatifan Demonstrates Durable Activity in Metastatic Clear Cell Renal Cell Carcinoma

November 1st 2024

Casdatifan was well tolerated and had durable clinical activity in patients with metastatic clear cell renal cell carcinoma.

Two Dana-Farber Cancer Institute Faculty Members Elected to the National Academy of Medicine

November 1st 2024

David Pellman, MD, and Matthew Vander Heiden, MD, PhD of Dana-Farber Cancer Institute have been named to the National Academy of Medicine.

FDA Approval Sought for Avutometinib Plus Defactinib in Recurrent KRAS+ Low-Grade Serous Ovarian Cancer

November 1st 2024

A rolling NDA seeking the approval of avutometinib plus defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer has been submitted to the FDA.

ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC

November 1st 2024

The phase 2 study of masofaniten plus enzalutamide in mCRPC naive to second-generation antiandrogen therapy has been discontinued.

Ameluz-PDT Leads to Target Lesion Clearance in Superficial Basal Cell Carcinoma

November 1st 2024

Ameluz-PDT generated statistically significant target lesion clearance outcomes vs placebo-PDT in superficial basal cell carcinoma.

Revisit Every OncLive On Air Episode From October 2024

November 1st 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

The Top News From ESMO 2024: A Variety of Data Inform Solid Tumor Landscapes

November 1st 2024

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Prevention and Early Recognition of Veno-Occlusive Disease Is Key to Reducing Post-Transplant Mortality

November 1st 2024

Marc J. Braunstein, MD, PhD, discusses the diagnosis, prevention, and treatment of patients with veno-occlusive disease post-transplant.

Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2– Breast Cancer

October 31st 2024

Hope Rugo, MD, FASCO, discusses the FDA approval of inavolisib, how it will be incorporated into care, and the patient population evaluated in INAVO120.

Technical Advances and Efforts to Bridge Care Gaps Take Center Stage During Breast Cancer Awareness Month

October 31st 2024

Sheldon M. Feldman, MD, discusses disparities, post-treatment care, and technological advancements in breast cancer during Breast Cancer Awareness Month.

ROSELLA Trial of Relacorilant Targets Stress Response to Overcome Chemoresistance in Ovarian Cancer

October 31st 2024

Domenica Lorusso, MD, PhD, and Premal Thaker, MD, highlight the upcoming phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer.

Rates of Taxane-Induced Peripheral Neuropathy Underscore Need to Tailor Treatment for Black Patients With Early Breast Cancer

October 31st 2024

Docetaxel treatment was associated with significantly less taxane-induced peripheral neuropathy vs paclitaxel in Black patients with breast cancer.

Sacituzumab Tirumotecan NDA for Pretreated EGFR+ NSCLC Accepted for Review in China

October 31st 2024

An NDA seeking the approval of sacituzumab tirumotecan for EGFR-mutant non–small cell lung cancer is under review by the NMPA’s CDE.

Sugemalimab Plus Chemotherapy Earns UK Approval in First-Line Metastatic NSCLC

October 31st 2024

First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.

Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer Patients

October 31st 2024

Results of the TALAPRO-2 trial showed that a novel prostate cancer therapy has a higher overall survival rate compared to the standard of care drug alone.

Effectively Targeting c-Met in Colorectal Cancer Is Becoming a Reality With Novel Approaches

October 31st 2024

John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC

October 31st 2024

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

FDA Delays PDUFA Date for Sotorasib Plus Panitumumab in KRAS G12C+ mCRC

October 30th 2024

The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.

Patient Communication is Key to Delivering Optimal PARP Inhibitor Treatment in Ovarian Cancer

October 30th 2024

Laura J. Chambers, DO, discusses the roles of niraparib and olaparib in ovarian cancer and the importance of patient communication throughout treatment.

Patients Characteristics, Sequencing Considerations Are Vital in Prostate Cancer Management

October 30th 2024

Bradley C. Carthon, MD, PhD, discusses recent data and the evolving treatment landscape in prostate cancer.